Traws Pharma Inc
TRAW2.180USD
-0.020-0.91%
Horário de mercado （ET）Cotações atrasadas em 15 min
15.41MValor de mercado
0.18P/L TTM
Mais detalhes de Traws Pharma Inc Empresa
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Informações de Traws Pharma Inc
Código da empresaTRAW
Nome da EmpresaTraws Pharma Inc
Data de listagemJul 25, 2013
CEODr. Iain D. Dukes, Ph.D.
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 25
Endereço12 Penns Trail
CidadeNEWTOWN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal18940
Telefone12677593680
Sitehttps://www.onconova.com/
Código da empresaTRAW
Data de listagemJul 25, 2013
CEODr. Iain D. Dukes, Ph.D.
Executivos da empresa Traws Pharma Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Chief Financial Officer
Chief Financial Officer
--
--
Ms. M. Teresa Shoemaker
Ms. M. Teresa Shoemaker
Independent Director
Independent Director
--
--
Dr. Werner Cautreels
Dr. Werner Cautreels
Director
Director
--
--
Dr. Trafford Clarke, Ph.D.
Dr. Trafford Clarke, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Symbio
2.73M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Symbio
2.73M
0.00%
Distribuição de ações
Atualizado em: qua, 24 de set
Atualizado em: qua, 24 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Viriom Inc
8.50%
OrbiMed Advisors, LLC
8.50%
Squadron Capital Management LLC
5.90%
Adage Capital Management, L.P.
4.63%
Savchuk (Nikolay)
3.54%
Outro
68.94%
Investidores
Investidores
Proporção
Viriom Inc
8.50%
OrbiMed Advisors, LLC
8.50%
Squadron Capital Management LLC
5.90%
Adage Capital Management, L.P.
4.63%
Savchuk (Nikolay)
3.54%
Outro
68.94%
Tipos de investidores
Investidores
Proporção
Private Equity
8.50%
Corporation
8.50%
Investment Advisor
6.27%
Hedge Fund
6.25%
Individual Investor
6.12%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.02%
Outro
61.75%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
49
1.68M
23.63%
-79.24K
2025Q2
57
2.78M
49.98%
+92.22K
2025Q1
59
3.22M
71.94%
+1.74M
2024Q4
58
1.47M
44.66%
+775.47K
2024Q3
57
942.34K
34.05%
+834.58K
2024Q2
58
213.81K
16.43%
+135.65K
2024Q1
55
74.05K
8.78%
-3.08K
2023Q4
60
70.75K
8.42%
-22.28K
2023Q3
70
76.41K
9.11%
-47.84K
2023Q2
73
78.91K
9.41%
-30.66K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Viriom Inc
605.53K
8.57%
--
--
Apr 28, 2025
OrbiMed Advisors, LLC
605.53K
8.57%
--
--
Jun 30, 2025
Squadron Capital Management LLC
420.50K
5.95%
+420.50K
--
Sep 12, 2025
Adage Capital Management, L.P.
330.00K
4.67%
--
--
Jun 30, 2025
Savchuk (Nikolay)
251.90K
3.57%
+168.68K
+202.70%
Apr 28, 2025
Vestal Point Capital, LP
149.80K
2.12%
-25.20K
-14.40%
Jun 30, 2025
Cautreels (Werner C)
98.35K
1.39%
-6.00K
-5.75%
Apr 28, 2025
Dukes (Iain D)
81.19K
1.15%
-2.03K
-2.44%
Apr 28, 2025
Alyeska Investment Group, L.P.
52.63K
0.75%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
35.73K
0.51%
+2.35K
+7.03%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
Data
Tipo
Proporção
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
